+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Female Contraceptive Market by Product Type, Mechanism, Distribution Channel, Generation, End User Age, Price Range - Global Forecast to 2030- Product Image
Female Contraceptive Market by Product Type, Mechanism, Distribution Channel, Generation, End User Age, Price Range - Global Forecast to 2030- Product Image
Sale

Female Contraceptive Market by Product Type, Mechanism, Distribution Channel, Generation, End User Age, Price Range - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904506
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Female Contraceptive Market grew from USD 9.91 billion in 2024 to USD 10.57 billion in 2025. It is expected to continue growing at a CAGR of 6.44%, reaching USD 14.41 billion by 2030.

Setting the Stage for the Female Contraceptive Landscape

The female contraceptive market stands at a pivotal juncture, shaped by evolving healthcare policies, technological breakthroughs, and shifting patient expectations. As public health institutions emphasize preventive care and individuals assert greater autonomy over reproductive health, contraceptive solutions have expanded beyond traditional methods to embrace innovation in drug delivery, digital health, and personalized medicine. This dynamic environment presents both opportunities and challenges for manufacturers, distributors, healthcare providers, and policymakers.

In this context, understanding the multifaceted drivers of demand, the impact of regulatory changes, and the competitive landscape is essential. This executive summary distills critical insights from primary and secondary research, expert interviews, and rigorous data analysis to guide decision-makers seeking to navigate the complexities of product development, market entry, portfolio optimization, and strategic partnerships. The objective is to equip stakeholders with a clear, actionable perspective on current dynamics and future trajectories.

Shifting Paradigms Transforming Contraceptive Choices

Over the past five years, the female contraceptive arena has experienced transformative shifts in response to advances in biomedical science and evolving consumer preferences. Hormonal delivery systems have become increasingly sophisticated, leveraging next-generation formulations and implant technologies that offer extended efficacy and improved side-effect profiles. At the same time, non-hormonal methods have regained prominence, driven by patient demand for natural and reversible options.

Parallel to technological progress, digital health platforms and telemedicine have emerged as pivotal channels for contraceptive education, prescription, and adherence support. Virtual consultations and mobile applications now integrate contraceptive counseling with menstrual tracking and symptom monitoring, fostering personalized care pathways. Moreover, the convergence of data analytics and patient engagement tools is enabling real-world evidence generation, which informs both clinical guidelines and commercial strategies.

Regulatory landscapes have also evolved, with several jurisdictions streamlining approval pathways for novel contraceptive modalities and introducing policy incentives to expand access. This environment has catalyzed collaborative ventures between established pharmaceutical companies and biotech innovators, accelerating time to market for breakthrough products. Collectively, these developments signal a new era in which patient-centricity, digital integration, and collaborative innovation define success.

Assessing the 2025 U.S. Tariff Implications on Contraceptive Access

The implementation of new United States tariffs in 2025 has exerted a measurable impact across the contraceptive supply chain, from raw material procurement to end-user pricing. Tariff adjustments on imported active pharmaceutical ingredients have prompted manufacturers to reassess sourcing strategies, with some electing to diversify supplier bases to mitigate cost volatility. This strategic response has underscored the importance of robust supplier risk management and regional manufacturing footprint optimization.

In markets heavily dependent on imported components, distributors have encountered margin compression, leading to incremental price adjustments for clinics, hospital pharmacies, and retail outlets. Although the tariff-driven cost increases have been partially absorbed by manufacturers through operational efficiencies, a portion has been passed on to healthcare providers and consumers. This trend has reignited discussions around healthcare affordability and the potential for policy interventions to safeguard access to essential contraceptive methods.

Despite these headwinds, the industry has demonstrated resilience through strategic partnerships and vertical integration. Several leading players have announced new domestic manufacturing initiatives, leveraging incentives and public-private collaborations to enhance supply security. As a result, the sector is poised to balance short-term tariff pressures with long-term capacity building, ensuring that patients continue to receive reliable and affordable contraceptive care.

Unveiling Market Segmentation to Reveal Growth Drivers

Insight into market segmentation reveals the intricate tapestry of female contraceptive adoption. When dissecting the market by product type, barrier methods, implants, injectables, intrauterine devices-further distinguished into Copper IUD and Hormonal IUD-and pills, which encompass combined pill and progestin-only pill variants, each category exhibits unique growth trajectories. Combined pills themselves span from first-generation to fourth-generation formulations, while progestin-only alternatives cater to patients with specific hormonal sensitivities.

Examining mechanism of action highlights the dichotomy between hormonal and non-hormonal methods. Hormonal approaches, subdivided into combined estrogen-progestin and progestin-only options, remain dominant due to well-established efficacy, whereas non-hormonal alternatives appeal to those seeking fewer systemic effects. Distribution channels further differentiate market dynamics: clinics and hospital pharmacies have traditionally served as primary access points, yet online pharmacies are rapidly gaining traction by offering convenience and discreet purchasing, while retail pharmacies continue to provide broad geographic coverage.

Generational analysis-first through fourth generation-illuminates shifts in side-effect profiles and patient tolerability, with newer generations prioritizing metabolic neutrality and minimal cardiovascular risk. Age-based segmentation identifies the highest uptake among women aged 25 to 34, followed by younger adults aged 15 to 24, and mature users aged 35 to 49, each group guided by distinct lifestyle considerations and risk-benefit perceptions. Finally, price range segmentation, spanning low-cost, mid-range, and premium offerings, underscores the market’s capacity to address both accessibility imperatives and demand for high-end, technologically advanced solutions.

Regional Dynamics Shaping Contraceptive Adoption Trends

Regional dynamics exert a profound influence on contraceptive adoption patterns and market evolution. Within the Americas, established healthcare infrastructures and extensive public health initiatives have driven high penetration of both hormonal and long-acting reversible contraception. However, rural and underserved communities continue to face disparities in access, prompting targeted outreach and telehealth solutions.

In Europe, Middle East & Africa, the landscape is highly heterogeneous. Western European nations exhibit mature markets characterized by comprehensive insurance coverage and robust generic competition, while emerging economies in the Middle East and Africa are experiencing rapid growth driven by demographic expansion and increasing healthcare investment. Variability in regulatory frameworks and cultural attitudes toward family planning necessitates localized strategies to tailor product offerings and educational campaigns.

The Asia-Pacific region presents a dichotomy between advanced markets such as Japan and Australia, which favor next-generation implants and intrauterine systems, and emerging economies in Southeast Asia and South Asia, where affordability and basic barrier methods remain predominant. Government-led family planning programs and public-private partnerships are key drivers of market development, as governments strive to improve maternal health outcomes and expand reproductive autonomy.

Competitive Landscape and Leading Industry Players

The competitive landscape of the female contraceptive market is anchored by a blend of established pharmaceutical giants and agile biotech innovators. Leading organizations continue to invest heavily in research and development, focusing on novel delivery systems such as biodegradable implants and transdermal patches that promise enhanced compliance and minimal side effects. Strategic alliances between major drug manufacturers and specialized medical device companies have accelerated the pipeline of next-generation intrauterine systems and implantable options.

At the same time, emerging players are capitalizing on niche segments, such as non-hormonal contraceptives and digital therapeutics, by leveraging breakthrough technologies in materials science and data analytics. These entrants often adopt a direct-to-consumer model, supported by digital marketing and telemedicine partnerships, to rapidly scale adoption among tech-savvy demographics. Concurrently, generic manufacturers are intensifying competition in high-volume segments like combined pills, driving down prices and widening access, particularly in markets with stringent cost-containment policies.

Across all tiers of the market, intellectual property strategies, patent cliffs, and lifecycle management initiatives remain central to corporate planning. Companies that balance innovative pipeline development with timely entry of biosimilars and generics are best positioned to capture market share and sustain long-term revenue growth.

Strategic Recommendations to Capitalize on Emerging Opportunities

Industry leaders should prioritize a multi-pronged approach that blends innovation, access, and patient engagement. Investing in advanced research collaborations to develop next-generation implants and non-hormonal methods will cater to growing demand for personalized solutions and side-effect management. Simultaneously, optimizing manufacturing footprints through strategic partnerships and regional facilities can mitigate supply chain risks and tariff impacts.

Expanding digital health capabilities is equally critical. Integrating mobile applications with telehealth services will enhance patient adherence and enable real-time data collection to inform clinical decision-making. By deploying targeted outreach and education initiatives, organizations can address unmet needs in underserved demographics and foster brand loyalty.

Finally, adopting dynamic pricing strategies and forging partnerships with public health agencies can broaden access across diverse economic segments. By balancing premium and low-cost offerings within a unified portfolio, companies can capture high-value opportunities while fulfilling social responsibility objectives.

Rigorous Research Approach Underpinning This Analysis

This analysis is grounded in a rigorous research methodology that integrates both qualitative and quantitative techniques. Secondary research involved exhaustive review of peer-reviewed journals, regulatory filings, company financial statements, and industry conference proceedings. Primary research included in-depth interviews with key opinion leaders, healthcare providers, payers, and patients across major geographies to capture nuanced perspectives on unmet needs and adoption barriers.

Data triangulation methods were employed to validate findings, combining survey results, proprietary databases, and real-world evidence studies. Market segmentation models were constructed using statistical analysis to identify high-potential subsegments by product type, distribution channel, demographic profile, and price tier. Regional market dynamics were assessed through country-level data points such as healthcare spending, reimbursement frameworks, and population demographics.

The resulting insights have been reviewed by a panel of subject-matter experts to ensure accuracy, relevance, and strategic applicability. This comprehensive approach delivers a balanced synthesis of market realities and forward-looking opportunities.

Concluding Perspectives on the Future of Female Contraceptives

The female contraceptive landscape is undergoing a period of sustained evolution, driven by innovation in drug delivery, digital health integration, and shifting policy environments. Stakeholders who align strategic priorities with patient-centric innovation, robust supply chain management, and adaptive market access strategies will emerge as frontrunners in a competitive marketplace.

Looking ahead, the convergence of biotechnology advances and digital therapeutics promises to unlock new avenues for personalized contraception that enhance safety, efficacy, and user satisfaction. At the same time, continued attention to affordability and equitable access will be essential to address global health objectives and maximize societal impact. By leveraging the insights and recommendations presented in this report, industry participants can navigate current challenges and seize emerging opportunities to shape the future of reproductive healthcare.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Barrier Methods
    • Implants
    • Injectables
    • Intrauterine Devices
      • Copper IUD
      • Hormonal IUD
    • Pills
      • Combined Pill
        • First Generation
        • Fourth Generation
        • Second Generation
        • Third Generation
      • Progestin Only Pill
  • Mechanism
    • Hormonal
      • Combined
      • Progestin Only
    • Non-Hormonal
  • Distribution Channel
    • Clinics
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Generation
    • First Generation
    • Fourth Generation
    • Second Generation
    • Third Generation
  • End User Age
    • 15-24 Years
    • 25-34 Years
    • 35-49 Years
  • Price Range
    • Low Cost
    • Mid Range
    • Premium
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Bayer Aktiengesellschaft
  • Organon & Co.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Johnson & Johnson
  • AbbVie Inc.
  • Viatris Inc.
  • Perrigo Company plc
  • Gedeon Richter Plc
  • Novartis AG

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Female Contraceptive Market, by Product Type
8.1. Introduction
8.2. Barrier Methods
8.3. Implants
8.4. Injectables
8.5. Intrauterine Devices
8.5.1. Copper IUD
8.5.2. Hormonal IUD
8.6. Pills
8.6.1. Combined Pill
8.6.1.1. First Generation
8.6.1.2. Fourth Generation
8.6.1.3. Second Generation
8.6.1.4. Third Generation
8.6.2. Progestin Only Pill
9. Female Contraceptive Market, by Mechanism
9.1. Introduction
9.2. Hormonal
9.2.1. Combined
9.2.2. Progestin Only
9.3. Non-Hormonal
10. Female Contraceptive Market, by Distribution Channel
10.1. Introduction
10.2. Clinics
10.3. Hospital Pharmacies
10.4. Online Pharmacies
10.5. Retail Pharmacies
11. Female Contraceptive Market, by Generation
11.1. Introduction
11.2. First Generation
11.3. Fourth Generation
11.4. Second Generation
11.5. Third Generation
12. Female Contraceptive Market, by End User Age
12.1. Introduction
12.2. 15-24 Years
12.3. 25-34 Years
12.4. 35-49 Years
13. Female Contraceptive Market, by Price Range
13.1. Introduction
13.2. Low Cost
13.3. Mid Range
13.4. Premium
14. Americas Female Contraceptive Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Female Contraceptive Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Female Contraceptive Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Bayer Aktiengesellschaft
17.3.2. Organon & Co.
17.3.3. Teva Pharmaceutical Industries Ltd.
17.3.4. Pfizer Inc.
17.3.5. Johnson & Johnson
17.3.6. AbbVie Inc.
17.3.7. Viatris Inc.
17.3.8. Perrigo Company plc
17.3.9. Gedeon Richter Plc
17.3.10. Novartis AG
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. FEMALE CONTRACEPTIVE MARKET MULTI-CURRENCY
FIGURE 2. FEMALE CONTRACEPTIVE MARKET MULTI-LANGUAGE
FIGURE 3. FEMALE CONTRACEPTIVE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. FEMALE CONTRACEPTIVE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. FEMALE CONTRACEPTIVE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. FEMALE CONTRACEPTIVE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COPPER IUD, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL IUD, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY PILL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 15-24 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 25-34 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 35-49 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY LOW COST, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY MID RANGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PREMIUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 69. CANADA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 70. CANADA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 71. CANADA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 72. CANADA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 73. CANADA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 74. CANADA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 75. CANADA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. CANADA FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 77. CANADA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 78. CANADA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 79. MEXICO FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 80. MEXICO FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 81. MEXICO FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 83. MEXICO FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 84. MEXICO FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 85. MEXICO FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. MEXICO FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 87. MEXICO FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 88. MEXICO FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 130. GERMANY FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 131. GERMANY FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 132. GERMANY FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 133. GERMANY FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 134. GERMANY FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 135. GERMANY FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 136. GERMANY FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. GERMANY FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 138. GERMANY FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 139. GERMANY FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 140. FRANCE FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 141. FRANCE FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 142. FRANCE FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 143. FRANCE FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 144. FRANCE FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 145. FRANCE FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 146. FRANCE FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. FRANCE FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 148. FRANCE FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 149. FRANCE FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 160. ITALY FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 161. ITALY FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 162. ITALY FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 163. ITALY FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 164. ITALY FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 165. ITALY FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 166. ITALY FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. ITALY FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 168. ITALY FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 169. ITALY FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 170. SPAIN FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 171. SPAIN FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 172. SPAIN FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 173. SPAIN FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 174. SPAIN FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 175. SPAIN FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 176. SPAIN FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. SPAIN FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 178. SPAIN FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 179. SPAIN FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 210. DENMARK FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 211. DENMARK FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 212. DENMARK FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 213. DENMARK FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 214. DENMARK FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 215. DENMARK FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 216. DENMARK FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. DENMARK FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 218. DENMARK FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 219. DENMARK FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 230. QATAR FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 231. QATAR FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 232. QATAR FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 233. QATAR FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 234. QATAR FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 235. QATAR FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 236. QATAR FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. QATAR FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 238. QATAR FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 239. QATAR FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 240. FINLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 241. FINLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 242. FINLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 243. FINLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 244. FINLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 245. FINLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 246. FINLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. FINLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 248. FINLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 249. FINLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 270. EGYPT FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 271. EGYPT FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 272. EGYPT FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 273. EGYPT FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 274. EGYPT FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 275. EGYPT FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 276. EGYPT FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. EGYPT FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 278. EGYPT FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 279. EGYPT FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 280. TURKEY FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 281. TURKEY FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 282. TURKEY FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 283. TURKEY FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 284. TURKEY FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 285. TURKEY FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 286. TURKEY FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. TURKEY FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 288. TURKEY FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 289. TURKEY FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 300. NORWAY FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 301. NORWAY FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 302. NORWAY FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 303. NORWAY FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 304. NORWAY FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 305. NORWAY FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 306. NORWAY FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. NORWAY FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 308. NORWAY FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 309. NORWAY FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 310. POLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 311. POLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 312. POLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 313. POLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 314. POLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 315. POLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 316. POLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. POLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 318. POLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 319. POLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 320. SWITZERLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 321. SWITZERLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 322. SWITZERLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 323. SWITZERLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 324. SWITZERLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 325. SWITZERLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 326. SWITZERLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 327. SWITZERLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 328. SWITZERLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 329. SWITZERLAND FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 330. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 331. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 332. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2030 (USD MILLION)
TABLE 333. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2030 (USD MILLION)
TABLE 334. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 335. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
TABLE 336. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 337. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 338. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2030 (USD MILLION)
TABLE 339. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY PRICE RANGE, 2018-2030 (USD MILLION)
TABLE 340. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 341. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 342. CHINA FEMALE CON

Companies Mentioned

The companies profiled in this Female Contraceptive market report include:
  • Bayer Aktiengesellschaft
  • Organon & Co.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Johnson & Johnson
  • AbbVie Inc.
  • Viatris Inc.
  • Perrigo Company plc
  • Gedeon Richter Plc
  • Novartis AG

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 10.57 Billion
Forecasted Market Value ( USD ) by 2030 $ 14.41 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Contraceptive Market - Global Forecast to 2030 - Product Image

Contraceptive Market - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From
Contraceptive Drugs and Devices Market Size, Share & Trends Analysis Report by Product (Contraceptive Drugs (Pills, Patch, Injectable), Contraceptive Devices), and Region with Growth Forecasts, 2025-2030 - Product Image

Contraceptive Drugs and Devices Market Size, Share & Trends Analysis Report by Product (Contraceptive Drugs (Pills, Patch, Injectable), Contraceptive Devices), and Region with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Contraceptive Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Contraceptive Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Contraceptive Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Contraceptive Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Contraceptive Market Size, Share, & Trends Analysis Report By Product (Contraceptive Devices, Contraceptive Drugs), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Contraceptive Market Size, Share, & Trends Analysis Report By Product (Contraceptive Devices, Contraceptive Drugs), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From

About the Female Contraceptive Market

The Female Contraceptive market is an important part of Women's Health, providing women with the ability to control their reproductive health. Contraceptives are used to prevent pregnancy, and can be divided into two main categories: hormonal and non-hormonal. Hormonal contraceptives, such as the pill, patch, and ring, use hormones to prevent ovulation and fertilization. Non-hormonal contraceptives, such as condoms, diaphragms, and spermicides, work by blocking sperm from entering the uterus. In addition to preventing pregnancy, contraceptives can also be used to treat a variety of conditions, such as endometriosis, polycystic ovary syndrome, and acne. Contraceptives can also be used to regulate menstrual cycles and reduce the risk of certain cancers. Some companies in the Female Contraceptive market include Bayer, Merck, Pfizer, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.